Congenital heart diseaseCohort study
Systemic Atrioventricular Valve Surgery in Patients With Congenitally Corrected Transposition of the Great Vessels
- Retrospective cohort study
Authors' conclusion
SAVV surgery remains a valuable option for the treatment of patients with ccTGA, with low early mortality and satisfactory long-term outcomes, particularly in those with SVEF ≥40%.
Study context
- Population
- Patients with congenitally corrected transposition (ccTGA) undergoing systemic atrioventricular valve (SAVV) surgery, 1979–2022
- Participants
- 108 patients
- Outcome
- Composite of:
- Mortality
- Cardiac transplantation
- Ventricular assist device implantation
Main finding
As reported in the abstract
Freedom from death or transplantation (actuarial)
- 5-year freedom from death or transplantation
- 92.4%
- 10-year freedom from death or transplantation
- 79.1%
- 20-year freedom from death or transplantation
- 62.9%
- Predictor of postoperative mortality: age at operation
- P = 0.01
- Predictor of postoperative mortality: preoperative SVEF
- P = 0.04
Observational data: associations, not effects.
Secondary outcomes
Freedom from valve reoperation, by prosthesis
P < 0.0001
10-year
20-year
Late postoperative systemic RV EF (SVEF), predictors
- Preoperative SVEF
- P < 0.001
- Complex ccTGA
- P = 0.02
- Severe SAVV regurgitation
- P = 0.04
- Preoperative creatinine
- P = 0.003
Baseline characteristics
- Median age at surgery (Q1-Q3: 28.8-51.0 years)
- 39.5 years
- Median preoperative SVEF (Q1-Q3: 33.2%-45.0%)
- 39%
- Intrinsic valve abnormality as mechanism of SAVV regurgitation
- 76.9%
Early postoperative mortality
- 1 patient
- 0.9%
Safety
Postoperative complete heart block
- 20 patients
- 18.5%
Original publication
Systemic Atrioventricular Valve Surgery in Patients With Congenitally Corrected Transposition of the Great Vessels. J Am Coll Cardiol. Published 5 December 2023. doi:10.1016/j.jacc.2023.09.822
Summarised from the published abstract; every number is checked against it